- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00758082
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients (TELFIT)
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study
TELFIT is a monocenter, controlled, randomised trial. It focuses on type 1 diabetes patients that have attended a functional insulin therapy training course. The Primary objective of the TELFIT study is to evaluate whether a PDA with telemonitoring by phone reinforces the effects of the functional insulin therapy training course as compared with conventional care.
Main judgment criteria: comparison of HbA1c means between M0 (start) and M3(3 months)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Grenoble, Frankrig, 38043
- University Hospital Grenoble
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Type 1 diabetes mellitus for ≥ 6 months or more
- Age > 18 year old
- The patient has attended a functional insulin therapy class or workshop
- Insulin basal-bolus therapy for at least 6 months. At inclusion, patients should be treated either with a long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
- Ability to understand how the PDA-phone works and ability to use it
- Social Security membership or benefit from Social Security
- Patients equipped with a memory blood glucose monitor
- Informed consent, with a signed and approved form
Exclusion Criteria:
- Underage patient, major patient under guardianship or protected by the Law
- Patient with any unstable associated evolutive pathology that could cause a diabetes imbalance within the coming year
- Change in diabetes treatment within the 3 months before inclusion or planned during the study
- Patient who needs a more frequent diabetic follow-up than in the protocol (especially severe or evolving complication due to diabetes)
- Patient attending another education program within the 3 months before inclusion or planning to attend one during the study
- Patient with toxicomania, alcoholism or psychological troubles that could impact the study
- Type-2-diabetic patient
- Patient who doesn't need strict metabolic objectives
- Pregnant or possibly pregnant woman
- Person with no freedom (prisoner)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: 1
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support
|
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support.
|
|
Eksperimentel: 2
PDA-phone + phone consultations + standard visit at 3 months
|
Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Comparison of HbA1c means
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Difference between theoretical insulin dose and actual dose, one week before the 3-month reevaluation session
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
DHP scale of quality of life and satisfaction dimension of the DQOL questionnaire
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Time spent by physicians and nurses in the different groups
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Weight changes during the 3-month period
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Number of hypoglycemias (moderate and severe) during the 3-month period
Tidsramme: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Pierre Y Benhamou, PhD, University Hospital, Grenoble
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2008-A00389-46
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .